|
Jul 2
|
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
|
|
Jul 2
|
Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements
|
|
Jul 2
|
Is Hims & Hers Stock in Trouble?
|
|
Jul 2
|
2 Growth Stocks to Buy Hand Over Fist in July
|
|
Jul 2
|
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
|
|
Jul 1
|
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
|
|
Jul 1
|
WeightWatchers and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care
|
|
Jul 1
|
Sector Update: Health Care Stocks Advance Tuesday Afternoon
|
|
Jul 1
|
Top Midday Stories: Powell Blames Tariffs for Rate Pause; Tesla Shares Fall on Trump-Musk Feud
|
|
Jul 1
|
Update: Market Chatter: Novo Nordisk Executives Ignored Warnings Against Wegovy Launch
|
|
Jul 1
|
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
|
|
Jul 1
|
Market Chatter: Novo Nordisk Executives Ignored Warnings Against Wegovy Launch
|
|
Jul 1
|
How Novo Nordisk misread the US market for its weight loss sensation
|
|
Jun 30
|
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
|
|
Jun 30
|
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
|
|
Jun 30
|
Hardman Johnston Global Equity Sold Novo Nordisk (NVO) due to Weak Script Trends
|
|
Jun 29
|
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
|
|
Jun 28
|
Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight
|
|
Jun 28
|
Hims & Hers' ugly split with Wegovy maker weighs on the telehealth company's future
|
|
Jun 28
|
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
|